First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
This article was originally published in The Pink Sheet Daily
Withdrawals call into question the remaining revenues the diabetes product can generate before its main patents expire.
You may also be interested in...
The waffling of India’s drug regulatory agency on the pioglitazone ban reveals cracks in the regulatory system.
Major players in the Indian drug industry expressed disappointment on the unilateral decision of the health ministry to ban pioglitazone and its combinations.
Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.